Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating and a $20 price target. Strong underlying fundamentals, continuous merger and acquisition activity, and alleviating medication pricing concerns are the reasons behind the firm's optimistic outlook for the biotech industry in 2026. Additionally, Barclays pointed out that ALT and other biotech stocks are still cheap in comparison to their pipeline potential. Altimmune, Inc. (NASDAQ:ALT) also announced on the same day that it intends to use the net proceeds from the offering for working capital, general company needs, and getting ready for its next Phase 3 MASH research. The FDA's Breakthrough Therapy Designation and positive Phase 2b 48-week findings bolster the company's claim that pemvidutide is a novel glucagon/GLP-1 dual agonist. Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for metabolic and liver dis
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]Seeking Alpha
- Altimmune Announces Closing of $75 Million Registered Direct Offering of Common StockGlobeNewswire
- Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationPR Newswire
- Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common StockGlobeNewswire
ALT
Earnings
- 11/6/25 - Beat
ALT
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 8-K
- 2/2/26 - Form 4
- ALT's page on the SEC website